Saphenous Vein Graft Interventions: Challenges and Strategies

Interventions for Saphenous Vein Grafts (SVG) remain a high-risk subset of percutaneous coronary intervention (PCI) due to the unique pathophysiology of graft degeneration. Unlike native vessel atherosclerosis, SVG plaque is often friable, lacks a fibrous cap, and is prone to distal embolization.

Clinical Challenges

• Embolic Phenomenon: The primary risk during SVG PCI is the “no-reflow” or “slow-flow” phenomenon, caused by the distal embolization of necrotic core material and fibrin.
• Restenosis Rates: Historically, SVGs have shown higher rates of Major Adverse Cardiac Events (MACE) and target lesion revascularization compared to native vessels.
• Graft Age: The risk of intervention increases significantly as the graft ages, particularly beyond the 5-to-8-year mark when degenerative changes become more pronounced.

Procedural Strategies

To mitigate risks and improve outcomes, several technical approaches are standard:

• Embolic Protection Devices (EPDs):
  • Distal Filters: The most common approach, allowing for continued blood flow while capturing debris.
  • Proximal Occlusion: Used less frequently but effective in specific anatomical subsets where a distal filter cannot be landed.
• Pharmacological Adjuncts:
  • Intracoronary vasodilators such as Nitroprusside, Verapamil, or Adenosine are often used to treat or prevent the no-reflow phenomenon.
  • The role of GP IIb/IIIa inhibitors is controversial in SVG PCI; while they reduce thrombus burden, they do not necessarily prevent embolization of friable plaque.
• Stent Selection:
  • Drug-Eluting Stents (DES): Current evidence favors second-generation DES over Bare-Metal Stents (BMS) to reduce target-vessel failure, though the benefit is less pronounced than in native coronary arteries.
  • Stent Sizing: Avoiding “aggressive” post-dilation is often preferred to minimize plaque protrusion and embolization.

Alternative Approaches

Given the high friability of older grafts, clinicians often weigh SVG PCI against other strategies:

• Native Vessel PCI: If the native circulation is amenable to revascularization (e.g., chronic total occlusion or high-grade stenosis), PCI of the native vessel is often preferred over the SVG due to better long-term patency.
• Medical Management: Optimization of intensive statin therapy and antiplatelet regimens.
• Redo CABG: Generally reserved for patients with multiple failing grafts and no viable PCI options, given the significantly higher surgical mortality of secondary procedures.

Comparison of Outcomes

Feature	Native Vessel PCI	SVG PCI
Plaque Type	Calcific/Fibrous	Friable/Thrombotic
Embolic Risk	Low	High
No-Reflow Risk	Minimal	Significant
Long-term Patency	High	Moderate to Low

---

Foundational Trials: Embolic Protection Devices (EPD)

The use of EPDs is a Class I recommendation in guidelines based on early randomized evidence showing a significant reduction in periprocedural major adverse cardiac events (MACE).

• SAFER Trial: This landmark study evaluated the GuardWire (distal occlusion) and demonstrated a 42% reduction in 30-day MACE compared to conventional wires (16.5% vs. 9.6%, p=0.001). It established that distal embolization is a primary driver of periprocedural MI in SVGs.
• FIRE Trial (2003): This trial confirmed that distal filter devices (specifically the FilterWire EX) are non-inferior to distal balloon occlusion (GuardWire), offering more technical flexibility by maintaining distal perfusion during the procedure.

Stent Selection: DES vs. BMS in SVG

While drug-eluting stents (DES) are superior in native vessels, their benefit in SVGs has been more nuanced due to the friable nature of vein graft plaques.

• DIVA Trial (2018): A multicenter, double-blind RCT comparing second-generation DES to BMS in 597 patients. At 1 year, there was no significant difference in the composite of cardiac death, target vessel MI, or target-lesion revascularization (TLR).
• ISAR-CABG Trial (2011/2018): This trial randomized 610 patients to DES or BMS. Long-term outcomes (up to 10 years) showed that DES were safe but did not provide a definitive long-term survival benefit or significant reduction in MACE compared to BMS in the SVG setting.

Recent Clinical Trials

Recent evidence has shifted toward refining the “lifetime management” of patients post-CABG, emphasizing native vessel PCI and optimized medical therapy.

• TACSI Trial (2025): Evaluated dual antiplatelet therapy (DAPT) vs. aspirin alone post-CABG for ACS. It found no ischaemic benefit but significantly increased major bleeding with DAPT, leading to recommendations for aspirin monotherapy in stable post-CABG patients.
• TOP-CABG (2025): Demonstrated that a time-limited intensification of therapy followed by aspirin alone resulted in non-inferior SVG occlusion rates with significantly lower bleeding risks.
• VELETI Trials: These explored stenting intermediate (30–60%) SVG lesions with DES versus medical therapy. VELETI I showed a decrease in luminal narrowing with DES. VELETI II concluded that sealing intermediate nonobstructive SVG lesions with DES was safe but was not associated with a significant reduction of cardiac events at 3-year follow-up.

Technical Predictors of Outcome

A pooled analysis of 3958 patients from the Harvard Clinical Research Institute EPD data set identified key angiographic predictors of 30-day MACE:

• SVG Degeneration Score: It is an ordinal metric of the extent of lumen irregularities and ectasia (>20% of the reference normal segment) within the SVG that makes up 25% (SVG degeneration score, 0), 26% to 50% (SVG degeneration score, 1), 51% to 75% (SVG degeneration score, 2), or >75% (SVG degeneration score, 3) of the total SVG length.
• Estimated Plaque Volume: Large plaque burdens remain the strongest predictor of “no-reflow” despite embolic protection.

---

References

• Agostoni, P., & Vermeersch, P. (2011). Percutaneous coronary interventions in saphenous vein grafts: the more things change, the more they stay the same. EuroIntervention, 7(8), 893–895.
• Bulluck, H., Bagur, R., & Mamas, M. A. (2018). Percutaneous coronary intervention of saphenous vein grafts: where do we stand? EuroIntervention, 14(2), 142–143.
• Coolong, A. (2008). Saphenous Vein Graft Stenting and Major Adverse Cardiac Events. Circulation. https://www.ahajournals.org/doi/10.1161/circulationaha.106.651232
• Hall, A. B., & Brilakis, E. S. (2019). Saphenous vein graft failure: seeing the bigger picture. Journal of Thoracic Disease, 11(S1441–S1444).
• Lee, M., & Kong, J. (2017). Current State of the Art in Approaches to Saphenous Vein Graft Interventions. Interventional Cardiology Review, 12(85).
• Neumann, F.-J., et al. (2018). 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 40(87–165).